Adenomatous Polyposis Coli: Clinical Trials

9 trials for Adenomatous Polyposis Coli, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 3 unknown, 1 recruiting, 1 terminated. 9 Phase 3, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 39Completed 3, Unknown 3, Recruiting 1, Terminated 1, Withdrawn 1
Phase 23Completed 2, Unknown 1

Follow Adenomatous Polyposis Coli: new trials by email Literature Review of Adenomatous Polyposis Coli trials Research Report on Adenomatous Polyposis Coli

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis
eRapa (encapsulated rapamycin), Placebo - Familial Adenomatous Polyposis (FAP)
Phase 3RecruitingRapamycin Holdings Inc.1682025-07-182026-06-02
Chemopreventive Effect of Combination of Celecoxib and Metformin in Patients With Familial Adenomatous Polyposis
celecoxib monotherapy, celecoxib and metformin combination - Familial Adenomatous Polyposis
Phase 3UnknownYonsei University282024-08-132024-08-09
Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis
Eicosapentaenoic acid free fatty acid (EPA-FFA), Placebo - Familial Adenomatous Polyposis
Phase 3UnknownS.L.A. Pharma AG2042018-12-052024-04-25
Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)
Eflornithine, Eflornithine Placebo, Sulindac 150 MG - Familial Adenomatous Polyposis
Phase 3CompletedCancer Prevention Pharmaceuticals, Inc.1712013-10-012021-06-08
A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)
Eflornithine plus Sulindac, Eflornithine plus Placebo, Sulindac plus Placebo - Familial Adenomatous Polyposis
Phase 3WithdrawnCancer Prevention Pharmaceuticals, Inc.2011-03-012015-04-24
Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis
Celecoxib, Ursodeoxycholic acid, Placebo - Familial Adenomatous Polyposis, Duodenal Neoplasms
Phase 2 / Phase 3CompletedRadboud University Medical Center372009-05-012013-05-16
Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA
Eicosapentanoic Acid (EPA), Endoscopy, Biopsies taken - Familial Adenomatous Polyposis Coli, FAP
Phase 2 / Phase 3CompletedS.L.A. Pharma AG582006-11-012014-08-22
Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)
Celecoxib, Placebo - Adenomatous Polyposis Coli
Phase 3TerminatedPfizer's Upjohn has merged with Mylan to form Viatris Inc.1062006-09-012021-02-21
Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) Patients
Ursodeoxycholic acid, Placebo - Adenomatous Polyposis Coli, Familial
Phase 2 / Phase 3UnknownAssistance Publique - Hôpitaux de Paris902004-10-012009-07-29

Narrower conditions

Polyps (4)  ·  Adenoma (2)  ·  Adenomatous Polyps (1)  ·  Colonic Polyps (1)  ·  Digestive System Diseases (1)  ·  Digestive System Neoplasms (1)  ·  Duodenal Neoplasms (1)  ·  Gastrointestinal Diseases (1)  ·  Gastrointestinal Neoplasms (1)  ·  Genetic Diseases, Inborn (1)  ·  Hyperplasia (1)  ·  Intestinal Diseases (1)  ·  Intestinal Neoplasms (1)  ·  Neoplastic Syndromes, Hereditary (1)

Broader conditions

Colonic Diseases (9)  ·  Colorectal Neoplasms (9)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (9)  ·  Intestinal Polyposis (9)  ·  Neoplasms (9)  ·  Neoplasms by Histologic Type (9)  ·  Neoplasms by Site (9)  ·  Neoplasms, Glandular and Epithelial (9)  ·  Adenomatous Polyps (8)  ·  Digestive System Diseases (8)  ·  Digestive System Neoplasms (8)  ·  Gastrointestinal Diseases (8)  ·  Gastrointestinal Neoplasms (8)  ·  Genetic Diseases, Inborn (8)  ·  Intestinal Diseases (8)

Interventions

Celecoxib (3)  ·  Eflornithine (2)  ·  Sulindac (2)  ·  Ursodeoxycholic Acid (2)  ·  Docosahexaenoic Acids (1)  ·  Eicosapentaenoic Acid (1)  ·  Endoscopy (1)

Sponsors

Cancer Prevention Pharmaceuticals, Inc. (2)  ·  S.L.A. Pharma AG (2)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (1)  ·  Radboud University Medical Center (1)  ·  Rapamycin Holdings Inc. (1)  ·  Yonsei University (1)

Countries

Italy (3)  ·  Netherlands (3)  ·  Spain (3)  ·  United Kingdom (3)  ·  United States (3)  ·  Belgium (2)  ·  Germany (2)  ·  Puerto Rico (2)  ·  Canada (1)  ·  Czechia (1)  ·  Denmark (1)  ·  France (1)  ·  Hong Kong (1)  ·  Hungary (1)  ·  Israel (1)

Top investigators

Alfred M. Cohen, M.D. (1)  ·  Bjorn WH van Heumen, MD (1)  ·  Carol Burke, M.D. (1)  ·  Ellen Kampman, Ph D (1)  ·  Fokko M Nagengast, MD, Ph D (1)  ·  Gary Shangold, MD (1)  ·  James Church, M.D. (1)  ·  Luigi Ricciardiello, MD (1)  ·  Nicholas J West, MB BS FRCS (1)  ·  Wilbert HM Peters, Ph D (1)  ·  Yann RA Parc, M.D., Ph.D. (1)

Results publications

PMID 20348368, PMID 21899713, PMID 23919274, PMID 24245549, PMID 32905675, PMID 34261858